1. Generics Bulletin
  2. >>Business

Gedeon Richter Strikes $16.5m Global Tocilizumab Deal

Agreement For Biosimilar To Actemra/RoActemra Reached With Taiwan’s Mycenax

 
• By Dave Wallace

Gedeon Richter has struck a deal worth $16.5m with Taiwan’s Mycenax for global rights to a tocilizumab biosimilar version of Actemra/RoActemra, setting a date for planned launches in the EU, Japan, Canada and Australia.

Tocilizumab_Injections
The deal provides Richter with a rival to Actemra/RoActemra • Source: Shutterstock

Gedeon Richter has struck a deal worth $16.5m with Taiwanese biotech firm Mycenax to gain global development, manufacturing and commercialization rights to the company’s proposed tocilizumab biosimilar version of Roche’s Actemra/RoActemra.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business